[Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance].

Abstract

BACKGROUND AND OBJECTIVE:

Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced non-small cell lung cancer (NSCLC) patients.

METHODS:

Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. Among the patients, 94.6% of them were suffering from adenocarcinoma. The percentage of female is 79.6%; the percentage of non-smoking is 80.6%. During the therapy period, follow-up was preformed every 2 months.

RESULTS:

Among the 93 patients, median therapy time was 16 months (range: 8 to 70 months), and 21.5% (20/93) of them had received therapy for more than 2 years, while 8.6% (8/93) had received that for more than 3 years. The progression included 80% (72/90) for intrapleural progression, 38.9% (35/90) for primary tumor plus recurrence after sugary especially, 51.1% (46/90) for intrapulmonary metastasis, 25.6% (23/90) for pleural metastasis, 30% (30/90) for intracranial progression and 15.6% (14/90) for intraperitoneal progression.

CONCLUSION:

Resistance to EGFR-TKI shows diversification in clinical observation, therefore, close clinical follow-up is necessary for early attention and timely treatment.

• Authors: Bin Wang, Xin Zhang, Lin Lin, Xuezhi Hao, Xiangru Zhang, Junling Li, Yuankai Shi
• Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer (Zhongguo Fei Ai Za Zhi) Vol. 16 Issue 10 Pg. 510-3 (Oct 20 2013) ISSN: 1999-6187 [Electronic] China
• PMID: 24113002 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Quinazolines
• ErbB Receptors
• Gefitinib

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Resistance, Neoplasm
• ErbB Receptors (antagonists & inhibitors)
• Female
• Gefitinib
• Humans
• Male
• Middle Aged
• Protein Kinase Inhibitors (therapeutic use)
• Quinazolines (therapeutic use)
• Retrospective Studies